Gemeinschaftsklinikum Mittelrhein

ETOPOSIDE FOR PRIMARY HLH - BETTER THAN ITS REPUTATION (2023) Lehmberg K, Ledig S, Wustrau K, Kontny U, Westphal S, Hundsdoerfer P, Jorch N, et al. Conference contribution Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience (2023) Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, et al. Journal article Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 (2023) Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt HC, Aguiar E, et al. Journal article Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial (2022) Roellig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Haenel M, et al. Conference contribution Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma (2022) Straka C, Schaefer-Eckart K, Hertenstein B, Bassermann F, Salwender H, Langer C, Kroenke J, et al. Conference contribution Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis (2022) Unglaub JM, Schlenk RF, Hanoun M, Reinhardt HC, Middeke JM, Schaefer-Eckart K, Steffen B, et al. Conference contribution MR imaging in children with transverse myelitis and acquired demyelinating syndromes (2022) El Naggar I, Cleaveland R, Wendel EM, Bertolini A, Schanda K, Karenfort M, Thiels C, et al. Journal article Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea (2022) Allard P, Alhaj N, Lobitz S, Cario H, Jarisch A, Grosse R, Oevermann L, et al. Journal article Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry (2022) Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schaefer-Eckart K, Steffen B, Sauer T, et al. Journal article Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative (2021) Kayser S, Schlenk RF, Lebon D, Carre M, Goetze KS, Stoelzel F, Berceanu A, et al. Journal article